Relafen 750, also known as naproxen, embodies a fascinating case study within the pharmacological pharmacy domain . Its mechanism of action primarily entails the preferential inhibition of cyclooxygenase catalysts, specifically COX-2, leading to a decrease in inflammatory synthesis. From a therapeut